Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Colorectal Neoplasms 2Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Hemorrhage 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 3Diphenhydramine 2Bendamustine Hydrochloride 2Acetaminophen 2obinutuzumab 1immunotoxin HA22 1ibrutinib 1fludarabine phosphate 1Vemurafenib 1Valganciclovir 1Therapeutics 1Specimen Handling 1Sodium Chloride 1Polymerase Chain Reaction 1Pentostatin 1Magnetic Resonance Imaging 1Histamine Antagonists 1High-Energy Shock Waves 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Famotidine 1Exercise Test 1Etoposide 1Epinephrine 1Electrocardiography 1Echocardiography 1Dexamethasone 1Cyclophosphamide 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Hairy Cell × Sodium Chloride × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡